Elscint returns with biomedical investment fund:
This article was originally published in Clinica
Executive Summary
Elscint, an Israeli company formerly known for its imaging businesses which it disposed of in 1998 for a total of $603 million, is moving back into early-stage biomedical investment. Elscint has set up Elscint BioMedical, a wholly owned subsidiary, funded with an initial $30 million to invest in early-stage companies in drug delivery, therapeutics and gene therapy. The company has already invested in Gamida Cell, another Israeli company, which is developing proprietary technology for multiplying embryonic stem cells.